Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T M Ludden

Showing results (61-70 of 124) with videos related to

Pageof 13
Sort By:
Investigational New Drugs|January 1, 1983
Pharmacokinetics of high dose melphalanM R Hersh, T M Ludden, J G Kuhn, et al.
Clinical Pharmacokinetics|June 1, 1992
Pharmacokinetics of quinidine in male patients. A population analysisC N Verme, T M Ludden, W A Clementi, et al.
Lancet (London, England)|February 7, 1976
Letter: Optimum phenytoin-dosage regimensT M Ludden, D W Hawkins, J P Allen, et al.
Journal of Pharmacokinetics and Biopharmaceutics|April 1, 1989
Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects modelsM S Driscoll, T M Ludden, D T Casto, et al.
Research Communications in Chemical Pathology and Pharmacology|March 1, 1982
The production of free fatty acids in post-heparin plasma during equilibrium dialysisS F Hamilton, E S Waller, G J Yakatan, et al.
Clinical Pharmacy|July 1, 1986
Evaluation of a Bayesian regression-analysis computer program for predicting phenytoin concentrationT M Ludden, S L Beal, C C Peck, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1978
Brain and plasma concentrations of amphetamine isomers in miceW H Riffee, T M Ludden, R E Wilcox, et al.
Clinical Pharmacokinetics|May 1, 1982
Clinical pharmacokinetics of hydralazineT M Ludden, J L McNay, A M Shepherd, et al.
Pharmacotherapy|January 1, 1991
Central issues relevant to clinical pharmaceutical scientist training programsR A Blouin, J C Cloyd, T M Ludden, et al.
Therapeutic Drug Monitoring|March 1, 1991
Sensitivity analysis of the effect of bioavailability or dosage form content on mean steady state phenytoin concentrationT M Ludden, S R Allerheiligen, T R Browne, et al.
Pageof 13

Showing results (61-70 of 124) with videos related to

Sort By:
Pageof 13
Investigational New Drugs|January 1, 1983
Pharmacokinetics of high dose melphalanM R Hersh, T M Ludden, J G Kuhn, et al.
Clinical Pharmacokinetics|June 1, 1992
Pharmacokinetics of quinidine in male patients. A population analysisC N Verme, T M Ludden, W A Clementi, et al.
Lancet (London, England)|February 7, 1976
Letter: Optimum phenytoin-dosage regimensT M Ludden, D W Hawkins, J P Allen, et al.
Journal of Pharmacokinetics and Biopharmaceutics|April 1, 1989
Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects modelsM S Driscoll, T M Ludden, D T Casto, et al.
Research Communications in Chemical Pathology and Pharmacology|March 1, 1982
The production of free fatty acids in post-heparin plasma during equilibrium dialysisS F Hamilton, E S Waller, G J Yakatan, et al.
Clinical Pharmacy|July 1, 1986
Evaluation of a Bayesian regression-analysis computer program for predicting phenytoin concentrationT M Ludden, S L Beal, C C Peck, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1978
Brain and plasma concentrations of amphetamine isomers in miceW H Riffee, T M Ludden, R E Wilcox, et al.
Clinical Pharmacokinetics|May 1, 1982
Clinical pharmacokinetics of hydralazineT M Ludden, J L McNay, A M Shepherd, et al.
Pharmacotherapy|January 1, 1991
Central issues relevant to clinical pharmaceutical scientist training programsR A Blouin, J C Cloyd, T M Ludden, et al.
Therapeutic Drug Monitoring|March 1, 1991
Sensitivity analysis of the effect of bioavailability or dosage form content on mean steady state phenytoin concentrationT M Ludden, S R Allerheiligen, T R Browne, et al.
Pageof 13